Last month a group of stakeholders convened to discuss current regulation of pharmacogenomics by the FDA. The opinions and recommendations of this group are described in a White Paper, accessible here. The topics transcend pharmacogenomics and offer lessons for the entire field of precision medicine.
The landscape of genetic testing early in life
The expanding landscape of consumer genetic health testing
Consumer genetic testing for health conditions has always been viewed with some skepticism by healthcare professionals. For many, direct-to-consumer (DTC) genetic testing was synonymous with 23andMe, whose health-related products are perceived as having little to no value for health care. But the landscape for consumer-initiated genetic health testing has changed dramatically in just the last year.
Pharmacogenomics in the Drug Package Insert
Many physicians turn to the FDA-approved drug label (package insert) for information about genetic testing that can be used to optimize drug response, also known as pharmacogenomics/pharmacogenetics (PGx). Information about PGx appears in the labels of hundreds of drugs, but how reliable and useful is this information?
The Evolving Landscape of Genetic Health Tests
The genetic testing landscape has changed dramatically in the past decades and continues to evolve as different delivery models and markets are being explored. In this post, we’ll discuss how the genetic testing industry has developed and some of the recent industry trends and factors impacting its growth.